Table 1.

Baseline characteristics

ID	age at NVP-HAART initiation	age at change to PI-HAART	months of follow-up on NVP-HAART	baseline VL (log copies/ml)	HIV subtype	population sequencing	treatment outcome
7a	3.5	-	21	7.2	C	WT	VF
9	11.5	died	6	6.7	A	WT	VF
11	12.6	33.6	21	7.4	A/C	WT	VF
17	4.2	9.6	3	7.2	D	WT	VF
19	3.6	8.1	3	5.4	A	WT	VF
22	3	15.6	12	6.2	A	K103KN	VF
24	2.1	14.1	12	6.6	C/D	WT	VF
2b	4.8	-	24	6.0	A	WT	int
3	7	21	12	6.5	A/C	WT	nf
4	2.4	10.5	6	6.6	A	WT	nf
8c	4.6	-	21	6.9	A	1AIT	nf
12	4.8	9.9	3	7.3	A	K103N	nf
14	4.2	8.1	3	7.4	A	G190A	nf
15	2.4	7.5	3	6.0	A	K103N	nf
18	7.4	20.4	12	6.4	A	WT	nf
20	5.1	9.9	3	6.3	D	WT	nf
28	4.5	8.1	3	6.9	C	WT	nf
29	7	17	9	5.4	A	WT	nf
30	6.9	14.9	6	6.1	A/D	WT	nf
32	5.1	9	3	7.1	A	WT	nf
Median	4.7	10.2	6	6.6

VL = viral load, age in months. VF = viral failure, int = intermittent viremia. nf = no failure

^athis mother reported NVP-HAART prior to pregnancy

^bsdNVP exposure unkown due to maternal death prior to enrollment

^cconflicting data on sdNVP exposure